Overview

• Officials said the tariffs, which were slated to begin Wednesday, did not take effect and remain under review.
• The Commerce Department is assessing companies’ plans to reshore production and offer Most Favored Nation pricing.
• President Trump threatened the 100% duty to push firms to build U.S. plants and said it would not apply to companies constructing domestic facilities.
• Industry analysts warn the levy could raise costs for patients and complicate global pharmaceutical supply chains and trade relationships.
• Drugmakers and healthcare providers face ongoing uncertainty and negotiations, and Pfizer disclosed a separate pricing agreement with the administration earlier this week.